Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent 

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

Translating Evidence to Practice to Improve Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

OncLive Peer Exchange® 

Videos

A panel of oncologists review recent data from the ZUMA-7 trial and provide a comprehensive review of thetreatment options for patients with R/R DLBCL.

Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).

Front-Line Treatment Options for Patients with DLBCL

Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).

An Overview of R/R DLBCL

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

Treatment Options for Patients with R/R DLBCL

Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.

L-MIND: Review of Long-Term Analyses Data

Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.

Role of CAR T-cell Therapy in Patients with R/R DLBCL

An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.

Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL

Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.

ZUMA-7: Clinical Implications

Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.

Sequencing Therapies in Patients with R/R DLBCL

Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.

Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

ZUMA-7: Clinical Implications

EP: 1.Front-Line Treatment Options for Patients with DLBCL

EP: 2.An Overview of R/R DLBCL

EP: 3.Treatment Options for Patients with R/R DLBCL

EP: 4.L-MIND: Review of Long-Term Analyses Data

EP: 5.Role of CAR T-cell Therapy in Patients with R/R DLBCL

EP: 6.Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL

EP: 7.ZUMA-7: Clinical Implications

EP: 8.Sequencing Therapies in Patients with R/R DLBCL

EP: 9.Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL

EP: 10.Future of R/R DLBCL

Latest Conference Coverage